MDX2201 Epstein-Barr Virus Vaccine Clinical Trials, Indication, News
ModeX Therapeutics's MDX2201, an Epstein-Barr virus (EBV) vaccine candidate, is based on ModeX's ferritin nanoparticle vaccine platform, which can express as many as 24 copies of a recombinant antigen on its surface to enhance the presentation of key components of the virus and stimulate durable protective immunity. MDX2201 presents antigens from four viral proteins involved in viral entry into host cells. These include a recombinant antigen designed from the proteins gH, gL, and gp42 and an antigen derived from gp350. By using ModeX's multi-targeted approach, this combination inhibits infection in two cell types, B and epithelial cells, which contrasts with efforts previously focused on gp350 alone.
This EBV vaccine technology was the subject of preclinical data published in May 2022 in Science Translational Medicine.
ModeX, an OPKO Health company, is based in Weston, Massachusetts. For more information, please visit www.modextx.com. OPKO (NASDAQ: OPK) is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, please visit www.opko.com.
MDX2201 Epstein-Barr Virus Vaccine Indication
According to the U.S. CDC, EBV is a member of the herpes virus family and is one of the most common human viruses. Most people are infected with EBV at some point during their lives. Since over 90% of adults have been infected with EBV, most adults will show antibodies to EBV. The presence of antibodies to both VCA and EBNA suggests past infection. EBV can cause infectious mononucleosis, also called mono, and is associated with other illnesses, including some specific types of cancer and multiple sclerosis. A sample of the patient's blood is required to perform a monospot test. There are currently no U.S. FDA-approved vaccines or treatments for EBV or herpes infections.
MDX2201 Epstein-Barr Virus Vaccine News
January 7, 2025 - "We are grateful to the participants and physicians who are actively engaged with Merck in our joint efforts to explore the potential of MDX2201 as a novel vaccine against EBV," said Elias Zerhouni, M.D., President and Vice Chairman of OPKO.
March 8, 2023 - OPKO Health, Inc. announced that ModeX Therapeutics, Inc., an OPKO Health company, entered into an exclusive worldwide license and collaboration agreement with Merck for the development of MDX-2201, ModeX's preclinical nanoparticle vaccine candidate targeting EBV.
MDX2201 Epstein-Barr Virus Vaccine Clinical Trials
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants.